TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02916979

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 daily for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan: 100 mg/m2 daily for 4 days

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rabbit ATG
Description: Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11
Study: NCT03942510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise with blood flow restriction
Description: High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise with blood flow restriction
Description: High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise with blood flow restriction
Description: High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercise with blood flow restriction
Description: High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
Study: NCT03775356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of hypotension and/or reduction of anesthetics
Description: The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
Study: NCT01830920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-184
Description: THR-184 is a synthetic oligopeptide administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-184
Description: THR-184 is a synthetic oligopeptide administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-184
Description: THR-184 is a synthetic oligopeptide administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-184
Description: THR-184 is a synthetic oligopeptide administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A normal saline solution identical in appearance to the active drug solution
Study: NCT02655627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity counselling via a brochure
Study: NCT04449042

Intervention type: PROCEDURE
Intervention: airway management during sedation or general anesthesia
Description: airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure

Intervention type: PROCEDURE
Intervention: airway management during sedation or general anesthesia
Description: airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure

Intervention type: PROCEDURE
Intervention: airway management during sedation or general anesthesia
Description: airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure

Intervention type: PROCEDURE
Intervention: airway management during sedation or general anesthesia
Description: airway management in children receiving sedation or general anesthesia for an elective, emergency, or urgent diagnostic or surgical procedure
Study: NCT04388059

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy at 2 and 5 cm from the pylorus on the postoperative weight loss, GLP1 levels and the glycemic control in morbid obese diabetic adolescents.
Study: NCT02985151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Syneron-Candela CO2RE Laser
Description: This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Syneron-Candela CO2RE Laser
Description: This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
Study: NCT03075033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shikani optical stylet
Description: Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic bronchoscope for
Description: AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
Study: NCT00636831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic: cefazolin Sodium
Description: 1g continuous IV at 30 minutes before starting operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic: cefazolin Sodium
Description: 1g continuous IV at 30 minutes before starting operation
Study: NCT01460251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
Study: NCT01081561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
Study: NCT00532597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low flux hemodialysis
Study: NCT00231868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Pelvic Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Pelvic Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel and Radiation Therapy
Description: Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour \& Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
Study: NCT01123785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-8875
Description: eye drops for 14 days in one eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched vehicle-control
Study: NCT01730677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: lapatinib 1000mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
Study: NCT01806233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
Study: NCT00004070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Study: NCT02239393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product).
Study: NCT03640351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1. Use of preservative free diquafosol ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery
Description: Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
Study: NCT02133183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01498523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: 600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: camel milk powder solution
Description: 72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: raw cow milk
Description: 50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose solution
Description: 25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
Study: NCT02921529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: false stimulation
Description: Electrodes were attached to specific acupoints without electric current
Study: NCT03965247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Rayotabs
Study: NCT03824353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Intelligence Training
Description: The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Healthy Living Program
Description: A placebo condition delivered online which presents health-related information only.
Study: NCT03486301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB001
Description: BDB001 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB001
Description: BDB001 is an immunotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Study: NCT03316391

Intervention type: OTHER
Intervention: Dosage of urinary podocyturia
Description: Dosage of urinary podocyturia at admission, delivery and post-partum visit
Study: NCT00603902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg once daily (QD)
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Study: NCT01002872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate (Fosrenol)
Description: Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill three times a day (TID) Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus \<3.5mg/dL Reduce to 1 pill twice a day (BID). If Phosphorus \>5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is \<3.5mg/dL Reduce to 1 pill daily. If phosphorus \>5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus \<3.5mg/dL stop the drug If phosphorus is \>5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial dose of placebo will be 1 pill three times a day
Study: NCT00972348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online access to a personal health record
Description: Patients in the intervention arm have full access to their online personal health record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No access to the PHR
Description: Patients will not be given access to their PHR but will complete online surveys.
Study: NCT00643058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS endotoxin
Description: Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)
Study: NCT01357616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5% ophthalmic solution
Study: NCT02961023

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise therapy
Description: 3-week residential phase and 12-week outpatient phase.~Residential phase~* Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~* A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~* 1.5 to 2 hours of exercise will be performed daily, with rest intervals.~* At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~* Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~* A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~* Participants will be provided with a cycle ergometer, weights and a HR monitor~* Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary
Study: NCT00603902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice a day (BID)
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Study: NCT02701530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted smoking cessation
Description: Smoking cessation program developed in cooperation with and aimed at smokers with low education.
Study: NCT03857217

Intervention type: DEVICE
Intervention: Extra-Corporeal Membrane Oxygenation
Description: ECMO is implanted in cardiac surgery patients.
Study: NCT02171312

Intervention type: DEVICE
Intervention: iDETECT Assessment
Description: The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.

Intervention type: DEVICE
Intervention: iDETECT Assessment
Description: The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.

Intervention type: BEHAVIORAL
Intervention: Routine Balance and Vestibular Testing
Description: A clinician will assess balance and vision by standard of care routine tests for neurologic function.